This protocol addresses childhood absence epilepsy (CAE) in patients where absence seizures are the only seizure type and there is no history of generalised tonic-clonic seizures. This specific presentation informs a distinct, evidence-based treatment choice that differs from broader-spectrum epilepsy management.
When absence seizures occur in isolation, without any accompanying generalised tonic-clonic events, major CAE trial data support a specific initial monotherapy approach. The seizure-type profile is the primary driver of drug selection at this stage.
For this presentation, initial monotherapy with ethosuximide (ETX) is the drug of choice, with dosing titrated gradually toward a target over successive weeks. The full structured regimen — including titration schedule, target parameters, and maximum limits — is available via the link below.
The primary goal is freedom from seizures: absence of both clinically apparent absence seizures and electrographic seizures on EEG, assessed at 16–20 weeks of treatment.
The treatment of choice for CAE with absence seizures only is ethosuximide.
Therefore, based on the CAE trial, ETX is the drug of choice as initial monotherapy for CAE, when absence seizures are the only seizure type, but there are specific treatment considerations for each drug, which are discussed below.
The initial target dosage of ETX is 20–30 mg/kg/day, usually divided into two doses. The initial dosage is typically around 10 mg/kg/day, with upward titration to the target every week.
The primary outcome measure was freedom from failure, defined as the absence of clinically apparent seizures (based on parent report) or electrographic seizures at 16–20 weeks of treatment, and the absence of treatment-limiting adverse effects.
View source ↗